Table 1.
Immunization trials of patients who have undergone bone marrow transplant (BMT)
| Country (ref.) year | Patient population (n) | Vaccine | Schedule | Response | Adverse events |
|---|---|---|---|---|---|
| Sweden (5),1982-1986 | Allogeneic (48) | TT | 1-3 doses beginning at 12 months | Higher response rate (100%) and levels in those receiving 3 doses | One severe local reaction |
| Finland (6),1985-1989 | Allogeneic (45) | TT | gp1: 6, 8, 14 months, gp2: 18, 20, 26 months | Antibody response similar for both schedules (100%) | None noted |
| Sweden (7) | Autologous marrow (52) or blood (38) | TT | 12, 13 and 14 or 18 months | 100% response in both patient groups | None noted |
| Sweden (10),1982-1987 | Allogeneic (55) | IPV | 1-3 doses beginning at 12 months | Higher response (92%) rate in those receiving >1 dose | Few minor local reactions |
| Sweden (11),1985-1991 | Autologous (35) | IPV | 12, 13, 14 months | Antibody levels higher after 3 doses | None noted |
| Finland (12),1985-1989 | Allogeneic (45) | IPV | gp1: 6, 8, 14 months, gp2: 18, 20, 26 months | Antibody responses similar for both schedules (100%) | None noted |
| Israel (16) | Allogeneic and autologous (27) | IPV | 2 doses 4-6 weeks apart 6-96 months | Non-statistically significant increase in % with antibodies | None noted |
| Finland (13),1985-1989 | Allogeneic (45) | Hib-con Pn | gp1: Hib 6 mos and Pn 8 months gp2: Hib 18 mos and Pn 20 months | Similar response (approximately 60%) to Hib in both groups. Poor response to Pn in both groups | None noted |
| United States (17),1990-1993 | Allogeneic and autologous (112) | Hib-con TT | gp1: 3, 6, 12 and 24 months gp2: 6,12 and 24 months gp3: 12 and 24 months | Similar responses 2 years post immunization in all groups | None noted |
| United States (19),1988-1990 | Allogeneic and Autologous (35) | Hib-con Pn,TT | gp1: 12 and 24 months gp2: 24 months | Higher antibody levels to TT and Hib in 2 dose group. Poor response to Pn | None noted |
| France (18) | Allogeneic (40) | Hib vs Hib-con | Two doses 1 month apart 4-79 months | Better response (85% vs 60%) in Hib-CPS-T | No serious |
| United States (21) | Allogeneic (39) | Pn | 1 dose 4-54 months | Small rise in antibody levels post vaccine, but less than normal controls | None noted |
| Sweden (14),1977-1985 | Allogeneic BMT (20) | MMR | 1 dose 2 or 3 years | Response rate: measles 77%, mumps 64%, rubella 75% | None |
Gp Group; Hib Haemophilus influenzae type b polysaccharide vaccine; Hib-con Haemophilus influenzae type b conjugate vaccine; IPV inactivated poliovirus vaccine; MMR measles, mumps, rubella vaccine; Pn pneumococcal polysaccharide vaccine; TT tetanus toxoid